Opdivo (Nivolumab)

nivolumab 100 mg/10 mL injection, 10 mL vial · INJECTION · PBS code 11906P

AUTHORITY_REQUIRED

What it costs

AU$1972.83 PBS-determined price per pack

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

• First listed on the PBS: 2020-03-01.
• Repeats: 5.
• PBS program: IN.

Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Stage IIIB, IIIC, IIID or Stage IV malignant melanoma

Initial treatment

The treatment must be in addition to complete surgical resection; AND

Patient must have a WHO performance status of 1 or less; AND

Patient must not have received prior PBS-subsidised treatment for this condition; AND

The treatment must commence within 12 weeks of complete resection; AND

Patient must not receive more than 12 months of combined PBS-subsidised and non-PBS-subsidised adjuvant therapy.

When nivolumab is initially prescribed as a 3-weekly dosing regimen, patients must only receive a maximum of 240 mg every 3 weeks for 2 cycles (i.e., 1 repeat). When prescribed as a weight based or flat dose adjuvant regimen, patients must only receive a maximum of 240 mg every 2 weeks or 480 mg every 4 weeks for a maximum of 12 months of adjuvant treatment.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Stage IIIB, IIIC, IIID or Stage IV malignant melanoma

Continuing treatment

Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND

Patient must have undergone surgical resection; AND

Patient must not have experienced disease recurrence; AND

The treatment must be the sole PBS-subsidised therapy for this condition; AND

Patient must not receive more than 12 months of combined PBS-subsidised and non-PBS-subsidised adjuvant therapy.

When prescribed as a weight based or flat dose adjuvant regimen, patients must receive a maximum of 240 mg every 2 weeks or 480 mg every 4 weeks for a maximum of 12 months of adjuvant treatment.

Sponsor: Bristol-Myers Squibb Australia Pty Ltd ABN 33 004 333 322

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.